A randomized trial of amifostine as radioprotector in the radiotherapy of head and neck cancer

Journal of B.U.ON.

Volumn 9, Issue 1, 2004, Pages 23-26

  Karacetin, Didem ^a   Yucel B ^a   Leblebicioglu B ^b   Aksakal, O ^a   Maral, O ^a   Incekara, O ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Amifostine; Head and neck cancer; Mucositis; Radioprotector; Radiotherapy; Xerostomia

Indexed keywords

AMIFOSTINE; ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; DEXAMETHASONE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CANCER RADIOTHERAPY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HUMAN; HYPOCALCEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PHARYNX DISEASE; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION PROTECTION; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND; STATISTICAL SIGNIFICANCE; TASTE DISORDER; VOMITING; XEROSTOMIA;

EID: 2442661630     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Harrison LB, Zelefski MJ, Pfitzher DG et al. Detailed quality of life assessment in patients treated with primary radiotherapy for cancer of the base of the tongue. Head Neck 1997; 19: 169-175.
2. Beeken L, Calman F. A return to normal eating after curative treatment for oral cancer. What are the long term prospects?. Eur J Cancer Oral Oncol 1994; 30B: 387-392.
3. Sauer R, Wannenmacher M, Wasserman T et al. A randomised phase III trial of radiation ± amifostine in patients with head and neck cancer. Proc Am Soc Clin Oncol 1999; 18: 392a (abstr 1516).
4. Shaw LM, Bonner HS, Schushter L et al. Pharmacokinetics of amifostine. Effects of dose and method of administration. J Clin Oncol 1999; 26 (Suppl 7): 34-36.
5. Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339-3345.
6. Brizel D, Saver R, Wannenmacher M et al. A randomized phase III trial of radiation ± amifostine in patients with head and neck cancer. Proc Am Soc Clin Oncol 1998; 17: 386a (abstr 1487).
7. Franzen L, Funegard U, Ericson T et al. Parotid gland function during and following radiotherapy of malignancies in the head and neck: A consecutive study of salivary flow and patient discomfort. Eur J Cancer 1992; 28: 457-462.
8. Wolf A, Fox PC, Ship JA et al. Oral mucosal status and major salivary gland function. Oral Surg Oral Med Oral Pathol 1990; 70: 49-54.
9. McDonald S, Meyerowitz C, Smudzin T et al. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 1994; 29: 747-754.
10. Niibe H, Takahashi I, Mitsuhashi N et al. An evaluation of the clinical usefulness of amifostine, radioprotective agent. A double-blind placebo controlled study in head and neck tumors. J Jpn Soc Cancer 1985; 20: 984-993.
11. Hensley ML, Schucter LM, Lindley C et al. American Society of Clinical Oncology Clinical Practice guidelines for the use of chemotherapy and radiotherapy protectans. J Clin Oncol 1999; 17: 3333-3355.
12. Takahashi I, Nagai T, Miyaishi K et al. Clinical study of the radioprotective effects of Amifostine (WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys 1986; 12: 1935-1938.
13. Büntzel J, Glatzel M, Kuttner K et al. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 2002; 12 (Suppl 1): 4-13.